Author
@BiotechCH BiotechCH
Biotech podcast/community hub delivering clinical-readout and deal-flow analysis with mixed sentiment
Aggregates and analyzes biotech/pharma news—clinical trial r
trader score
+1.42
hit rate
56%
mean α
+0.74%
signals 14d
20
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 16 scored bets: 56% hit rate, +0.74% mean alpha, trader score +1.42. Their last-14d mentions, direction-adjusted, have moved +1.4% since posting (mean over 9 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-16 | ALEC | @BiotechCH | +0.45 | Preclinical data show 75%-80% tau mRNA knockdown and support interest in ALEC's BBB approach. | -0.5% | tweet ↗ |
| 2026-10-16 | DNLI | @BiotechCH | +0.05 | Early clinical data suggest ARWR successfully delivered an siRNA antibody conjugate. | · | tweet ↗ |
| 2026-10-16 | ARWR | @BiotechCH | +0.55 | Early clinical data suggest ARWR successfully delivered an siRNA antibody conjugate. | +3.8% | tweet ↗ |
| 2026-10-16 | TEVA | @BiotechCH | +0.30 | Highlights encouraging cross-indication data and upcoming catalysts for three biotech firms. | -5.0% | tweet ↗ |
| 2026-10-16 | ARGX | @BiotechCH | +0.40 | Highlights encouraging cross-indication data and upcoming catalysts for three biotech firms. | +6.7% | tweet ↗ |
| 2026-10-16 | TRAX | @BiotechCH | +0.30 | Highlights encouraging cross-indication data and upcoming catalysts for three biotech firms. | · | tweet ↗ |
| 2026-10-16 | TRAX | @BiotechCH | +0.50 | TRAX and ARGX reported positive celiac-disease trial data ahead of a November meeting. | · | tweet ↗ |
| 2026-10-16 | ARGX | @BiotechCH | +0.50 | TRAX and ARGX reported positive celiac-disease trial data ahead of a November meeting. | +6.7% | tweet ↗ |
| 2026-10-16 | MIRM | @BiotechCH | +0.60 | MIRM announced positive Phase 3 data and plans to file for an expanded indication. | +0.3% | tweet ↗ |
| 2026-10-16 | · | @BiotechCH | · | Argues IPF drug development has poor Phase 2-to-Phase 3 translation and warrants skepticism. | · | tweet ↗ |
| 2026-10-16 | BMY | @BiotechCH | +0.10 | BMY's Phase 3 IPF trial was significant only at low dose, though approval is viewed as plausible. | +2.9% | tweet ↗ |
| 2026-10-16 | · | @BiotechCH | · | Says investor appetite remains strong for differentiated biotech with clinical catalysts. | · | tweet ↗ |
| 2026-10-16 | · | @BiotechCH | · | Describes a biotech flight to quality and innovation despite transient market pressures. | · | tweet ↗ |
| 2026-10-16 | · | @BiotechCH | · | Expects further rate increases and warns they previously pressured biotech. | · | tweet ↗ |
| 2026-10-16 | · | @BiotechCH | · | Argues a string of biotech acquisitions could restore confidence and end the bear market. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.